A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.J. D. Wright, A Alvarezsecord, +7 authors David G. MutchJournal of clinical oncology : official journal…20065019 Background: Bevacizumab has shown activity in recurrent ovarian cancer with an acceptable adverse event profile. However, the incidence of bowel perforation in a recent trial of heavily… (More)